secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-01-13T23:59:59+00:00
Accession:  0001370053-23-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio authorizes $50M stock repurchase plan; cash >$575M
-------------------------------------------------------------

- Board authorized repurchase of up to $50M of common stock through Dec 31, 2023.
- Cash, equivalents, and investments >$575M as of Dec 31, 2022.
- Reiterates ~4 years of capital to execute R&D plan, excluding potential GSK royalties.
- Repurchases may occur in open market under Rule 10b5-1 and 10b-18; no obligation to buy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000010/0001370053-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000010/anab-20230113.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer